- Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers - - Preliminary data on WTX-124 administered in combination with pembrolizumab show similar tolerability to WTX-124 monotherapy - - Additional details and data post abstract cut-off date to be presented at ASCO - - Company to host webcast to review these data on Monday, June 3, 2024, at 8:00 am ET - WATERTOWN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc.

-最新的单药剂量递增数据继续表明，WTX-124在检查点抑制剂治疗复发/难治性癌症患者中具有良好的耐受性和临床活性-与pembrolizumab联合使用的WTX-124的初步数据显示出与WTX-124单药治疗相似的耐受性-额外的细节和数据摘要截止日期将在ASCO上呈现-公司将于2024年6月3日星期一上午8:00主持网络广播，以审查这些数据-马萨诸塞州沃特敦，2024年5月23日（环球新闻社）-狼人治疗公司。

(the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the upcoming presentation of clinical data from dose-escalation arms of the Phase 1/1b trial evaluating WTX-124, its conditionally activated Interleukin-2 (IL-2) INDUKINE™ molecule, as monotherapy and in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy.

（the“Company”或“Worewolf”）（Nasdaq:HOWL）是一家创新的生物制药公司，开创了开发条件性激活疗法的先河，旨在刺激人体免疫系统治疗癌症，今天宣布即将推出1/1b期试验剂量递增组的临床数据，该试验评估WTX-124，其条件性激活的白细胞介素-2（IL-2）INDUKINE™分子，作为单一疗法，并与pembrolizumab联合用于检查点抑制剂治疗后局部晚期或转移性实体瘤患者。

Highlights from the data as of January 28, 2024, were published today in an abstract for the upcoming poster presentation, which will include additional data from a May 1, 2024, cut-off date, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 - June 4 in Chicago, Illinois.

截至2024年1月28日的数据摘要今天发布在即将举行的海报展示的摘要中，其中将包括2024年5月1日截止日期的其他数据，该日期将于5月31日至6月4日在伊利诺伊州芝加哥举行的2024年美国临床肿瘤学会（ASCO）年会。

“We are very pleased by WTX-124 clinical results published in today’s abstract, which not only build upon initial monotherapy tolerability, biomarker and clinical activity data presented last Fall at SITC but also establish a similarly well-tolerated profile in combination with pembrolizumab,” said Daniel J.

Daniel J。

Hicklin, Ph.D., P.

希克林博士，P。